A retrospective analysis of Medicare data revealed that between 2000 and 2017, immunohistochemistry claims associated with melanoma diagnoses grew from 11% to 51%. Rising utilization — and substantial geographic variation in practice patterns — argue for further research to optimize IHC use in the diagnoses of melanoma, according to the authors.
"Given the extensive use of IHC in clinical practice," the authors concluded, "studies examining the resulting outcomes of IHC on different domains, such as symptom burden, quality of life, and mortality, are crucial." "However," he told this news organization, "the histologic diagnosis of melanoma is sometimes substantially subjective — and all physicians, including pathologists, even though they are not providing care in the physical presence of the patient, are fiduciaries." If an IHC stain would meaningfully improve a patient's care, he said, physicians should attempt to provide it, unless strictly disallowed by a payer.
Malignant Melanoma Skin Cancer Malignant Skin Neoplasm Dermatopathology California Immunohistochemistry Medicare Biologic Therapy Biologics Cancer Malignant Neoplasia Carcinoma Malignant Neoplasm Clinical Guidelines Guidelines New York Colorado Cutaneous Melanoma Epidemiology Grant Jobs Career Profession Employment Job Interview Job Contract Employment Contract Kentucky
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: Medscape - 🏆 386. / 55 Read more »
Source: SciTechDaily1 - 🏆 84. / 68 Read more »
Source: IntEngineering - 🏆 287. / 63 Read more »
Source: PhillyInquirer - 🏆 81. / 68 Read more »
Source: Medscape - 🏆 386. / 55 Read more »
Source: washingtonpost - 🏆 95. / 72 Read more »